Yasmeen Rahimi; Analyst; Piper Sandler & Co. Good day and thank you for standing by. Welcome to the Nektar Therapeutics fourth quarter 2024 financial results conference call. (Operator ...

Nektar Therapeutics (NKTR) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.

Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s rezpegaldesleukin in atopic dermatitis – AD ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a price target of $7.00. The company’s shares closed ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), currently trading at $0.87 with a market capitalization of $162.5 million, announced today that it has achieved target enrollment for its Phase ...

SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Wednesday reported fourth-quarter earnings of $7.3 million. The San Francisco-based company said it had net income of 3 ...

(RTTNews) - Below are the earnings highlights for Nektar Therapeutics (NKTR): Earnings: $7.26 million in Q4 vs. -$42.08 million in the same period last year. EPS: $0.03 in Q4 vs. -$0.22 in the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Fourth Quarter 2024 financial results conference call. At this time, all participants are in a listen-only mode.

Nektar Therapeutics (NKTR) reported its Q4 2024 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $0.03, compared to the forecasted loss of $0.16. The company’s ...

Breakout star Osa Odighizuwa is among the league's best defensive tackles and one of Dallas' biggest priorities entering the offseason, with former first-round pick Mazi Smith as the lone proven ...